SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (the Company; bluebird) today announced updates to be presented at the 42 nd Annual J.P. Morgan Healthcare conference including ...
- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three ...
Recipharm Advanced Bio, a segment of CDMO Recipharm, and Infant Bacterial Therapeutics (IBT) began a process performance qualification (PPQ) for IBT’s lead product, IBP-9414. The PPQ program will take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results